Absence of the Platelet Receptor for Drug-Dependent Antibodies in the Bernard-Soulier Syndrome

THOMAS J. KUNICKI, MARGARET M. JOHNSON, and RICHARD H.ASTER, Milwaukee Blood Center, Inc.; the Department of Biology, Marquette University; the Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53233; and the Wilmington Medical Center, Wilmington, Delaware 19899

ABSTRACT The platelet membrane receptor for quinidine- and quinine-dependent antibodies was studied in three patients with the Bernard-Soulier syndrome (BSS) and in normal subjects with immunologic techniques based on the release of 51Cr from labeled platelets. The receptor could not be detected on BSS platelets but was present on platelets from each of 180 normal subjects. BSS platelets reacted normally with other allo- and autoantibodies. In confirmation of previous reports, BSS platelets were found to be deficient in glycoproteins Ib and Is. However, after apparently total cleavage of these proteins from the membrane of normal platelets by controlled hydrolysis with trypsin or chymotrypsin, 80% of the drug-dependent antibody receptor activity was retained. These observations suggest the existence of an additional, hitherto unrecognized membrane defect in Bernard-Soulier platelets.

INTRODUCTION

The Bernard-Soulier syndrome (BSS)1 is an inherited disorder of blood platelets characterized by reduced platelet-subendothelial adherence (1, 2), moderate thrombocytopenia, a long bleeding time, and giant platelets in the peripheral blood smear (1–3). BSS platelets, in contrast to normal platelets, fail to aggregate in response to bovine Factor VIII (2, 4) or human Factor VIII and ristocetin, but respond normally to other aggregating agents such as adenine diphosphate (2, 5, 6). Deletion of a platelet membrane glycoprotein, designated glycoprotein I (GPI),2 in BSS was first reported by Nurden and Caen (10). With newer analytic methods capable of resolving the GPI band into three proteins on sodium dodecyl sulfate polyacrylamide gel electrophoresis, this abnormality has been more precisely defined as a deficiency of both GPIb and GPls but not of GPIg (8, 11).

Our recent observation of a deletion of the alloantigen PI41 from platelets of patients with Glanzmann’s thrombasthenia (12) prompted us to evaluate platelet-specific antigen markers in BSS platelets. We here report the apparently unique deletion from BSS platelets of a membrane receptor (antigen?) specific for quinidine- and quinine-dependent platelet antibodies.

METHODS

Patient selection. Each of the three patients studied fulfilled the diagnostic criteria of BSS noted above. Patients 1 and 2 were first cousins who have been the subjects of several previous studies (2, 13, 14). Patient 3 was kindly referred by Dr. Scott Murphy of Philadelphia, Pa.

Methods. Platelets were isolated by differential centrifugation as previously described (12) except that residual erythrocytes were washed three additional times with EDTA in 145 mM NaCl to increase platelet yields. Clumping of platelets, characteristic of BSS, was observed in each preparation. This was reversed by repeated centrifugation and resuspension of the isolated platelets. The final yield of platelets from each preparation of whole blood was ≈70%. Final preparations contained fewer than one erythrocyte or leukocyte per 1,000 platelets.

Selection of antibodies reactive with PI41 antigen, quinidine- and quinine-dependent antiplatelet antibodies, and autoantibodies of idiopathic thrombocytopenic purpura and techniques for 51Cr-labeling of platelets, the 51Cr-release assay, and assay of antibody-reactive sites by inhibition of 51Cr release have been described (12). Membrane glycoproteins were separated by polyacrylamide gel electrophoresis of solubilized whole platelets with or without 10% 2-mercaptoethanol, followed by scanning

GPIIbα, mol wt 132,000; GPIIIa, mol wt 115,000. Molecular weight values are those determined in fully reduced (10% 2-mercaptoethanol) samples.

Received for publication 30 May 1978.

1 Abbreviations used in this paper: BSS, Bernard-Soulier syndrome; GPI, glycoprotein I.

2 The membrane glycoprotein terminology originally proposed by Phillips (7) is used with the modification for the GPI complex proposed by Nurden and Caen (8), that is, GPIb-α, membrane bound; GPIs, soluble, identical to glyocalcin (9); GPIg, granule associated, mol wt 145,000–155,000;
densitometry of periodic acid Schiff reagent-stained gels (7, 12).

RESULTS

Antibody-induced release of $^{51}$Cr from platelets. In contrast to platelets from each of 180 normal subjects studied in our laboratory, platelets from the three BSS patients failed to respond to quinine- and quinidine-dependent antibodies by releasing $^{51}$Cr (Fig. 1). Platelets from the same three BSS patients responded normally, however, to antibodies reactive against the platelet-specific antigen, PlAl (15) (Fig. 2), with two autoantibodies from patients with idiopathic thrombocytopenic purpura, and with a serum containing multiple anti-histocompatibility antigen antibodies obtained from a multitransfused patient (not shown).

Inhibition of $^{51}$Cr lysis. We have previously shown that antibody-reactive sites on the platelet surface can be assayed by determining the ability of known numbers of platelets to inhibit the action of a cytolytic antibody on $^{51}$Cr-labeled target platelets (12). By this means it was found that the BSS platelets contain no detectable sites reactive with quinine- or quinidine-dependent antibodies (Fig. 3). The PlAl antigen was found to be expressed normally on BSS platelets in the same assay (not shown).

Polyacrylamide gel electrophoresis of solubilized platelets with and without pretreatment with enzymes. Platelets from the three BSS patients exhibited a strik-

![Figure 1](image-url)  
**Figure 1** Lysis of $^{51}$Cr-labeled platelets from normal (A, B, C) and BSS (1, 2, 3) donors by a quinine-dependent, antiplatelet antibody. Ordinate denotes percent release of $^{51}$Cr induced by quinine-dependent antiserum in dilutions indicated on the abscissa. Control subjects A, B, and C were studied simultaneously with patients 1, 2, and 3, respectively. The shaded area denotes lysis (±2 SD) observed with platelets from 22 normal individuals. Comparable results were obtained with two quinine-dependent antibodies.

![Figure 2](image-url)  
**Figure 2** Lysis of $^{51}$Cr-labeled platelets from normal and BSS donors by antibody reactive with the platelet-specific antigen, PlAl (legend as in Fig. 1). Shaded area denotes lysis (±2 SD) observed with platelets from 12 normal individuals including control subjects A, B, and C. Comparable results were obtained with three different anti-PlAl antibodies.

![Figure 3](image-url)  
**Figure 3** Inhibition of the lytic activity of quinidine-dependent, antiplatelet antibody by nonlabeled platelets from three BSS patients (1, 2, 3) and from normal subjects (A, B, C). 20 µl of nonlabeled platelets in 0.013 M phosphate buffer, 145 mM NaCl, pH 7.4, was incubated with 20 µl of quinidine in 0.013 M phosphate buffer, 145 mM NaCl, pH 7.4, and 20 µl of quinidine-dependent antibody for 2 h at 37°C. The final concentration of quinidine was 10 µM and the final concentration of platelets was varied as indicated on the abscissa. Complement and $^{51}$Cr-labeled platelets were then added and percent immune lysis (ordinate) was determined after an additional 2 h of incubation. Inhibition curves shown for normal subjects A, B, and C are typical of those obtained with 50 normal subjects studied to date. Platelets from the BSS patients failed to inhibit $^{51}$Cr release, even at a final platelet concentration of $300 \times 10^9$ per mm$^3$ (not shown). BSS platelets inhibited anti-PlAl antibody to the same extent as platelets from normal subjects (not shown).
ing reduction of GPI on gels stained with periodic acid Schiff reagent, in confirmation of earlier reports (8, 11). Levels of GPIIb and GPIIIa were within normal limits.

GPIIb and GPIs of intact normal platelets were hydrolyzed with minimal concentrations of trypsin and chymotrypsin exactly as described by others (9, 10). In confirmation of Nurden (10), GPI was completely removed from the membrane by trypsin within 1 min as judged by visual inspection and scanning of polyacrylamide gel preparations. Chymotrypsin removed GPI more slowly, over a period of 20 min. After 30 min of treatment with either enzyme, 80% of the initial quinine-dependent antibody receptor activity remained intact as determined with the inhibition assay.

DISCUSSION

Our findings indicate that BSS platelets, in contrast to those of all normal subjects tested and those from patients with another inherited disorder of platelet function, Glanzmann's thrombasthenia, are incapable of binding quinidine- and quinine-dependent platelet antibodies in the presence of the appropriate drug. Deletion of the receptor (antigen?) for these antibodies appears to be specific because BSS platelets reacted normally with antibodies having PI and histocompatibility antigen specificities and with autoantibodies from patients with idiopathic thrombocytopenic purpura. The recent finding that BSS platelets are deficient in GPIs and GPIIb, the major constituents of platelet membrane GPI (8, 11), led us to treat normal platelets with trypsin and chymotrypsin to determine whether reactivity with drug-dependent antibodies would be lost in parallel with GPI. However, antibody receptor activity was preserved almost totally after prolonged treatment of platelets with either enzyme. In normal platelets, the receptors for drug-dependent antibodies are located exclusively on the external surface of the plasma membrane. Thus, our findings suggest the existence of an abnormality of the BSS platelet membrane in addition to deletion of GPIs and GPIIb. Alternatively, the receptor for drug antibodies may lie on a segment of GPIIb proximal to the membrane which is not subject to enzymatic degradation.

Acute, severe thrombocytopenia resulting from sensitivity to certain drugs has been recognized as a clinical entity for nearly 100 years. More than 50 drugs have been implicated as causes of this type of thrombocytopenia but only two, quinidine and quinine, account for at least two-thirds of the observed cases (16). Early workers suggested that thrombocytopenia in this disorder was a consequence of the binding of certain drugs to some constituent of the platelet membrane where they acted as haptenic antigens. Recently ac-

quired evidence, however, suggests a causative role for drug-antibody complexes which have an extremely high affinity for some receptor on the platelet membrane (17). Thus, platelets are destroyed as "innocent bystanders" upon ingestion of the drug. The receptor with which the presumed complexes react has been found on platelets of all normal subjects studied to date, but is not expressed on other blood cells (15).

Our observations appear to provide a new clue to the molecular basis of the functional defect in BSS platelets and suggest that the underlying abnormality in this disorder may be more complex than previously believed. BSS platelets also may provide a new tool for characterization of the membrane receptor with which drug-dependent antibodies react. It seems possible that a more complete understanding of this receptor and of the mechanism of drug-antibody-membrane interaction may be relevant to a spectrum of drug-dependent immunologic phenomena affecting tissues other than platelets.

ACKNOWLEDGMENTS

We wish to thank Mr. Charles Powell (Milwaukee Blood Center, Inc.) for his capable technical assistance in a segment of this work.

This work was supported by grant HL-13629 from the National Heart, Lung, and Blood Institute and by a research fellowship from Marquette University.

REFERENCES


*Drug-Dependent Antibody Receptor in Bernard-Soulier Syndrome*